Traditional drug manufacturing and drug delivery process development requires a huge time and financial investment. Pharmaceutical and biopharmaceutical leaders are leveraging the power of in silico approaches.
Watch Now
In an increasingly complex and global pharmacovigilance environment, the need for more effective and easier collaboration is accelerating adoption of cloud technologies.
Watch Now
pharmaphorum
Brexit uncertainty isn’t going away any time soon – but it’s important to remember that the UK government has already set out two plans for the future shape of the country’s healthcare industry: the second Life Sciences Sector Deal and the long-term plan for the NHS. With these two plans in place there are plenty of opportunities for the industry and the government to work together to keep the UK at the top of the international life sciences sector – and perhaps reach even greater heights.
Watch Now
catalent
The pharmaceutical industry has experienced a trend in the number of accelerated approval designations for drugs (e.g. orphan drugs, breakthrough therapies, accelerated approvals, and FDA priority reviews) being developed. These designations are given shortened timelines for product development, product assessment and commercial scale-up (typically between 3-5 years) and come with several development and manufacturing challenges. In this webinar, you will hear from industry experts on overcoming scale-up challenges and fit-for-purpose manufacturing strategies.
Watch Now